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Background: Cardiac metastases from renal cell carcinoma without vena caval involvement are extremely rare with a
limited number of cases reported in the worldwide literature until now. Nevertheless, this rare location of metastasis
may significantly influence patient treatment and prognosis. Cooperation between oncology, cardiology, and urology
teams are indispensable in cases of patients suffering from intramyocardial tumors. For these individuals, treatment
guidelines based on large-scale studies are unavailable and only case/case series analysis may provide clinicians with
decision assistance.
Case presentation: In this paper, we report a case of a 50-year-old Caucasian male diagnosed with a 10.2 × 10.3 ×
10.0 cm lower pole left renal mass in January 2002. He was subsequently treated with immunochemotherapy, tyrosine
kinase inhibitors (TKIs), and mTOR inhibitors (mTORIs) - that is sunitinib, everolimus, and sorafenib. In March 2012,
contrast-enhancing tumors in the left myocardium (∅22 mm) and in the interventricular septum (∅26 mm) were seen
on CT. Cardiology testing was conducted and the patient was treated with pazopanib with a profound response.
Overall survival since the clear cell renal cell carcinoma (ccRCC) diagnosis was 11 years 2 months and since diagnosis
of multiple heart metastases was 1 year.
Conclusions: Cardiac metastases present a unique disease course in renal cell carcinoma. Cardiac metastases may
remain asymptomatic, as in the case of this patient at the time of diagnosis. The most common cardiac presentation
of renal cell carcinoma is hypertension, but other cardiac presentations include shortness of breath, cough, and
arrhythmias. Targeted systemic therapy with tyrosine kinase inhibitors may be useful for this group of patients, but
necrosis in the myocardium can result in tamponade and death. Regular cardiac magnetic resonance imaging scans
are required for treatment monitoring.
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Rare locations of metastasis may significantly influence
patient treatment and prognosis. For these individuals,
treatment guidelines based on large-scale studies are un-
available, and only case/case series analysis may provide
clinicians with decision assistance. The incidence of pri-
mary and secondary heart tumors in unselected path-
ology necropsy reports is about 0.17% with secondary
tumors more common. Secondary cardiac tumors are
often found incidentally in even up to 20% of patients with
metastatic cancer, sarcoma, or lymphoma [1]. Metastases* Correspondence: anna.czarnecka@gmail.com
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unless otherwise stated.spread to the pericardium, myocardium, and endocardium
in descending order of frequency [2].
In general, cardiac metastases are 20 to 40 times more
common than primary cardiac malignancies, and have
been reported in different studies in approximately 2%to
18% of cases at autopsies. Intramyocardial metastases
arise most often in the course of malignant melanoma,
leukemia, lymphoma, and lung, esophageal and breast
cancers [3,4]. At the same time, heart involvement
via the inferior vena cava (IVC) is a well-known phe-
nomenon in clear cell renal cell carcinoma (ccRCC)
cases. Renal cell carcinoma (RCC) is known for invading
the renal vein and further promoting tumor thrombosis
of the vena cava and even the right atrium [1]. For these
patients, long-term outcome after radical surgical treat-
ment with RCC and tumor thrombus extension reachingral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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with median survival (including in-hospital mortality)
of 25 months. Cardiopulmonary bypass with deep
hypothermic circulatory arrest allows safe and precise
extirpation of all intracaval and intracardiac tumor mass
[5]. Manual repositioning of the tumor thrombus out of
the right atrium into the inferior vena cava on the beating
heart is also a safe and feasible approach with low risk of
tumor thrombembolization [6].
In the absence of IVC involvement, cardiac metastases
are exceptional in ccRCC with a limited number of cases
reported in the worldwide literature (Table 1) [3]. No cases
of well-documented cardiology diagnostics or oncological
follow-ups with noted progression-free survival (PFS) and
overall survival (OS) have been described in the literature
before (Tables 1 and 2). No such cases have been reported
in clinical trial of recently widely used sunitinib, sorafenib,
pazopanib or axitinib [7-10]. In this report, we present the
first case of a patient with intramyocardial metastases
treated with tyrosine kinase inhibitors (TKI), who was
carefully monitored.
Case presentation
We report a case of a 50-year-old Caucasian male who
was diagnosed with a 10.2 × 10.3 × 10.0 cm lower pole
left renal mass in January 2002. Subsequently, he under-
went radical left nephrectomy in that same month.
Pathology of the resected tumor was ccRCC, Fuhrman
Grade 2. In the following year, metastasis in the right ad-
renal gland was diagnosed and the patient was referred for
a metastasectomy, which was performed in September
2003, when a 6.1 × 5.5 × 4.9 cm metastatic tumor was re-
moved. Subsequently, he was enrolled in immunochem-
otherapy treatment.
Between September 2003 and January 2004, the pa-





(N = 55-70) [U/l]
CKMB 39 11
(N = 0–16) [U/l]
Troponin I 0.070 0.055
(N <0.035, MI > 0.12) [ng/ml]
NT-proBNP 799.4 -
N < 125 [pg/ml]
LDH 243 -
(135–232) [U/l]
Treatment Pazopanib IFNa regimen of vinblastine, interleukin-2, and interferon
alpha-2a (IFN-α-2a) in a single dosage of 4 mg intraven-
ous vinblastine per m2 of body surface, 4.5 MU/m2 sub-
cutaneous interleukin-2 q12h, qw1,3,5 and 3 MU/m2
subcutaneous interferon alpha-2a qd, qw 2,4,6 [27]. The
immunochemotherapy was terminated due to stenocar-
dial chest pain without myocardial ischemia signs. After
metastasectomy and immunochemotherapy, the patient
remained disease free until 2006 when multiple right
lung and right femoral bone metastases were diagnosed
at a routine check-up. In September 2006, bi-lobectomy
of the right lung was performed, and in November 2006,
the patient underwent a total right hip replacement.
Total rib replacement with subsequent rehabilitation en-
abled the patient to walk without walking aid (cane,
crutches or walker) until final deterioration (see below).
All surgical specimens were confirmed as ccRCC.
In March 2007, new lung lesions were detected, and in
April 2007 the patient was started on immunotherapy of
9 MU subcutaneous interferon alpha-2a qd, qw 1,3,5
with moderate tolerance of body temperature elevation
up to 100.0°F, grade 3 neutropenia, myalgia, arthralgia
and bone pain. The lung disease progressed after seven
months from the beginning of the immunotherapy and
he was transferred to sunitinib treatment beginning in
November 2007 at a standard dose and schedule (50 mg,
4/2 weeks). After six cycles, the dose was reduced to
37.5 mg due to hand-foot syndrome and mucositis grade
3. The patient continued sunitinib treatment with the
best response of stable disease (SD) and received a total
of 15 cycles. Pamindronate disodium 90 mg adminis-
tered monthly was prescribed in parallel due to bone le-
sions with concurrent hypercalcemia. In October 2009,
the patient underwent a femoral bone intramedullary
locking ChM nail placement in order to prevent patho-
logic fracture.ented case
02.08. 08.01. 30.01. 15.02.
2012 2013 2013 2013
58 20 16 16
13 13 11 23
0.066 0.097 0.076 0.076
- - 1875.0 1879.3
178 - 134 196
IFN Axitinib BSC BSC
Table 2 Summary of all reported cardiac intramyocardial metastases in clear cell renal cancer and the course of
disease in those patients
Case no Localization Reference
Years from
nephrectomy Signs or symptoms Diagnostic method Treatment; treatment efficacy
1 LV [11] 23 Weight loss CT, TTE, MRI, CA ND
2 LV [12] 18 Dyspnea CT, CA Surgery - successful, 6 years follow-up
3 LV [13] 7 Chest pain TTE, TEE, CT, B Chemotherapy - no response
4 LV [4] 0 ND PET-CT ND
5 LV [14] ND Dyspnea CT, TTE ND
6 LV, PE [3] 8/12 Dyspnea, asthenia, and inferior
limb edema, peripheral cyanosis
TTE No
7 LV, PE [15] ND ND ND Surgery - successful
8 RA [16] ND Asymptomatic TTE, CT Surgery - successful
9 RA, LA, LV, PE [13] 7 Endocarditis TTE, CT, CA Chemotherapy - no response
10 RV [17] 19 ND ND Surgery - successful
11 RV [18] 18 Asymptomatic PET-CT Sunitinib, everolimus - successful PR
6 months
12 RV [1] 4.5 Arrhythmia, tachycardia MRI, EBCT, CA, ECG,
TEECG
Immunotherapy - no response
13 RV [19] 5 Congestive heart failure
(NYHA class III)
MRI, CT, CA, TEE Echo-guided coil embolization -
successful, 19 months follow-up
14 RV [20] 0 Pansystolic murmur TTE, MRI ND
15 RV [21] 0 Syncope, T wave abnormality,
prolonged QT interval
ECG, TTE Surgery - successful
16 RV [22] ND Presyncope TTE, B ND
17 RV [23] ND Asymptomatic ND ND
18 RV [24] ND ND X-ray Surgery – died
19 RV [25] ND Dyspnea Post-mortem diagnosis ND
20 RV, SE [26] 4 cardiac murmur, monomorphic
ventricular tachycardia
TTE Sunitinib, ICD
21 SE [2] 20 Raynaud’s-like phenomena,
systolic ejection murmur
TTE, MRI, TEE, B Surgery -successful
Legend: TTE - Transthoracic echocardiography; TEE – transesophageal echocardiography, PA – pulmonary arteries, RA – right atrium, RV – right ventricle, SE- septum,
CA - Coronary angiography, B- biopsy; ICD - implantable cardioverter-defibrillator, ND – no data available; EBCT - electron-beam CT; TEECG – trans -esophageal ECG;
S-S; M-M; PE - pericardial effusion.
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the patient was rescheduled on everolimus 10 mg/day. This
treatment was continued with the best response of SD
for the next 23 months (2009–2011), and was accom-
panied by zoledronic acid injections. As a result of
a solitary new metastasis in the right kidney, the pa-
tient was referred for nephron-sparing surgery (NSS),
which was performed in August 2010. In April 2011,
multiple new skin metastases developed and the pa-
tient was referred for surgical consultation. In May
2011, scalp metastases were removed. After four weeks’
recovery in July 2011, the patient started sorafenib (2 ×
200 mg b.i.d.) treatment. From 2011 to2012, sorafe-
nib treatment was continued with SD for 7 cycles on
standard dose. The patient tolerated the treatment well
with reported neuropathies grade 2. Standard follow-upcontrast-enhanced-CT scan was performed after 9 sorafe-
nib cycles (March 2012). Metastases in the thoracic and
abdominal lymph nodes, liver, right kidney, pancreas and
skeleton were stable, but new lesions in the right lung
(33 × 17 mm), in the right lumbar retroperitoneal re-
gion (27 × 20 mm), and in the psoas major muscle
(∅10 mm) were described.
Moreover, contrast-enhancing tumors in the left myo-
cardium (∅22 mm) and in the interventricular septum
(∅26 mm) were described (Figure 1). This was defined
as disease progression and the patient was transferred to
pazopanib treatment in April 2012. In parallel, further
laboratory tests and medical imaging were carried out
(Table 2, Figure 2). In order to specify the diagnosis,
we referred the patient for an echocardiogram that
confirmed a 16 × 19 mm tumor localized between the
Figure 1 First CTimaging showing intramyocardial tumor in the LV in the left myocardium (white arrow 1A and 1B) and in the
interventricular septum (red arrow 1A and 1B).
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mated ejection fraction (EF) of 60%.
A subsequent cardiac MRI performed in April 2012
revealed multiple intramyocardial metastases (Figure 2),
including tumors localized in segments: 1) apical inferior
and apical lateral (∅13 × 7 mm); 2) apical septal and
mid-inferoseptal (3 tumors: ∅10 mm, 11 mm, and
14 mm); 3) basal anterior (∅13 mm); 4) basal anterosep-
tal (∅18 mm); 5) mid-anteroseptal with pericardium in-
filtration (44 × 31 × 26 mm); and also in 6) anterior
(∅14 mm) and posterior papillary (∅13 mm) muscles of
the left ventricle (LV). On cardiac MRI, the EF was mea-
sured at 49.6% and hypokinetic muscles were described
in the septum and anterolateral mid-ventricular seg-
ment. Cardiac single-photon emission computed tomog-
raphy (SPECT) confirmed impaired myocardial perfusion
in the inferolateral wall of the LV and anterior apex. Al-
though the patient developed no signs or symptoms of
cardiac dysrhythmia, a 24-hr Holter electrocardiogram
(ECG) was performed and revealed ST-segment elevation,
atrial extrasystoles, premature ventricular complexes, and
a single episode of atrial fibrillation.
After five months of standard pazopanib treatment, a
cardiac MRI in July 2012 (Figure 2) revealed SD with
massive necrosis in the tumor localized in septal seg-
ments and an EF of 45%. At this point, the 24-h Holter
ECG revealed no rhythm abnormalities. Due to massive
necrosis – a typical TKI treatment effect – the patientwas referred for IFN-alpha treatment and received IFN-
α-2a 3 million U, three times weekly for two months.
This treatment was terminated due to poor tolerance
with significant myalgia, arthralgia, and severe bone
pain. In August 2012, a follow-up CT revealed progres-
sion according to RECIST-1.1 criteria with new lung and
peritoneal tumors. In November 2012, axitinib treatment
in a reduced dose (5 mg) was initiated. After two cycles
of treatment, the patient’s condition deteriorated and the
patient passed in March 2013. OS since ccRCC diagnosis
was 11 years 2 months, since first TKI treatment was
5 years 3 months, and since diagnosis of multiple heart
metastases was 1 year.
Conclusions
Metastatic ccRCC involving the heart is well-recognized
but a rare phenomenon, mostly arising as an intravascu-
lar protruding tumor. According to literature since 2000,
right atrial in-growth of RCC was recently diagnosed in
no more than 1% of cases at the time of nephrectomy.
In post-mortem studies, cardiac metastasis was shown
to be present in 11% of patients who died of RCC [3].
There are two mechanisms of cardiac involvement.
Tumor extension through the renal vein and IVC is the
main mechanism for the spread of cardiac ccRCC. On
the other hand, metastases may also arise by diffuse
systemic blood-borne spread or through the intratho-
racic lymphatic system, especially in the presence of
Figure 2 Cardiac-MRI performed on treatment onset and follow-up showing multiple (2A, 2B, and 2C) intramyocardial tumors and
large necrosis on TKI treatment - coronal, horizontal and sagittal sections.
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is clear that left ventricular metastases from ccRCC with-
out vena caval or right atrial involvement are casuistic
(Table 1). In the absence of either direct vena caval exten-
sion or systemic disease, involvement of the heart is
extremely rare with only two cases known [12]. This spe-
cific pattern of metastasis should be considered a Stage 4
disease, with an expected five-year survival of less than
10% [20]. Up until now, only 21 cases of intramyocardial
tumors of ccRCC have been described in the literature
(Table 1). Majority of these cases were single tumors.Only reports by two groups have shown multiple cardiac
metastases from ccRCC [3,13]. Moreover only in two
cases, the patients were treated with TKI, but in both
cases, cardiac tumors were single, and no cardiac tests
were reported nor was functional testing evaluation per-
formed. In one of the cases the tumor actually developed
on sorafenib treatment [14]. Other disease course and
treatment is required if is a tumor thrombus that pro-
trude to the heart, but not develop as intramyocarial me-
tastases. In particular it was shown that tumor thrombus
level does not predict recurrence or mortality in this
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ment in the renal vein (Group 1) or subdiaphragmatic
IVC tumor thrombus (Group 2), in comparison to in-
volvement of IVC above diaphragm or atrial extension
(Group 3). Survival is determined by inherent aggressive-
ness of the cancer manifested by tumor size, grade and
distant metastasis at presentation [28]. Pre-surgical treat-
ment with sunitinib is able to ease surgery for ccRCC
tumor thrombi and surgery after sunitinib treatment may
be possible without additional morbidity. In this setting,
two courses of pre-surgical therapy with sunitinib may be
appropriate treatment [29].
Most ccRCC cardiac metastases remain asymptomatic,
as in the case of this patient at the time of diagnosis.
The most common cardiac presentation of renal cell car-
cinoma is hypertension, but other cardiac presentations
include shortness of breath, cough, arrhythmias, chest
pain, important hemodynamic impairment, and periph-
eral edema [21]. Tachyarrhythmia is also found often in
this patients and may lead to syncope [21]. Coronary oc-
clusion or compression from tumor masses can lead to
myocardial infarction, heart failure, and death [12]. A
typical clinical pattern of cardiac ccRCC disease progres-
sion is characterized by a worsening performance status,
exacerbation of cardiac symptoms, including tampon-
ade, arrhythmia, obstruction, or dilated cardiomyopathy,
representing one of the terminal events as in the case of
the reported patient [30]. Coronary occlusion or compres-
sion from tumor masses may also lead to myocardial
infarction and death [12]. Pericardial involvement with
effusion and cardiac tamponade is the most commonly
recognized cause of hemodynamic compromise [24].
A variety of diagnostic imaging and hemodynamic
techniques have been applied in the diagnostic process
of all cases published, including echocardiography, CT,
MRI, and even right heart catheterization and right ven-
triculography [24]. In our opinion cardiac MRI could be
the diagnostic tool of choice in the assessment of pa-
tients with RCC when cardiac metastasis is suspected
(Figure 2). Although there is overlap of the MRI charac-
teristics of several cardiac masses, MRI is reliable tool to
exclude lipomas, fibromas, and hemangiomas as well
as thrombus or lipomatous hypertrophy. Also necrosis,
extra-cardiac spread, and pericardial effusion may be
identified with cardiac MRI [31]. Transthoracic echocar-
diography, transesophageal echocardiography, and PET-
CT may also be used to diagnose cardiac metastases
[20,30]. The capability of PET for absolute quantification
in general and for blood flow quantification in particular
is a substantial advantage. As we have shown in this case
with SPECT, cardiac lesions visualized by functional im-
aging are correlated with anatomic data and provides
sensitivity as well as the specificity of scintigraphic find-
ings. Myocardium perfusion and coronary morphologycan be evaluated with SPECT/CT systems. For assessing
absolute flow and coronary flow reserve imaging with
SPECT also appears to be reliable [32]. Targeted sys-
temic therapy may be useful for this group of patients
[11], but profound necrosis in the heart wall may evoke
tamponade, therefore follow-up cardiac MRI scans are
required. Resection or embolization of ccRCC cardiac
metastasis is dependent on the location and relationship
of the tumor to the important local structures [11,19].
Finally, based on experience with this patient and litera-
ture data, we propose regular cardiac magnetic resonance
imaging (MRI) evaluation in ccRCC patients receiving
TKI treatment when intramyocardial ccRCC metastases
are found. We believe that MRI combines noninvasive
multiplanar imaging and the ability to acquire functional
information with excellent contrast resolution [31].
Finally this case presents prolonged treatment with mul-
tiple lines of TKIs and mTOR inhibitor after immunother-
apy. At this point of time third line therapy - following
first-line TKI and mTOR inhibitors remains undefined, al-
though sunitinib and other VEGF inhibitors have demon-
strated activity in this setting [33]. Re-challenge with TKIs
may provide clinical benefit in terms of PSF/OS after
everolimus in patients with mRCC [34], as in this case. Re-
cent data analysis has proven that globally PFS durations is
shorter and response rate lower on re-challenge following
initial treatment, but longer interval between treatments
was shown to increase response to sunitinib re-challenge
[35]. In a wide retrospective analysis in the sorafenib –
mTOR inhibitor – sunitinib group subsequent PFS was of
11.7, 5.1 and 9.1 months, respectively, while in the suniti-
nib – mTOR inhibitor – sorafenib group PFS was 14.4, 4.3,
and 3.9 months, respectively. This has led to conclusion
that there is no significant difference between the two se-
quence modalities [36]. After failure of everolimus,
re-exposure to TKIs was recently reported as a common
clinical practice. It was demonstrates that patients obtain
clinical benefit of therapies beyond immunotherapy –
sunitinib/sorafenib – everolimus sequence. Drugs admin-
istered beyond was sunitinib (in 28.6% cases), sorafenib
(in 28.6%) and other therapies (in 42.8%) in a recent re-
port [37]. It was also shown that sunitinib and sorafenib
re-challenge may be considered as it has had potential
benefits in terms of PFS and may be tolerated in select
mRCC patients [38,39]. This treatment modality may be
effective due to a transient nature of sunitinib resistance
[40,41] and in primarily sunitinib-responsive patients,
re-challenge with sunitinib may be successfully intro-
duced after mTOR inhibitor - refractory disease [42].
This case also confirms that sequential therapy enables
to obtain prolong combined PSF as result of multiple
lines of treatment. Although this patient obtained benefit
from presented sequence immunotherapy – sunitinib –
everolimus – sorafenib – pazopanib – axitinib, but for
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be hoped that TKIs, mTORIs with novel therapies
(anti-PDL1, anti-PD1 anti-CTLA4) used in combin-
ation or sequentially have potential to provide best
treatment and favorable outcomes in ccRCC. Results
from ongoing and planned trials are expected to help
shape future therapy [43].
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